Operations and clinical assesment core

运营和临床评估核心将负责整合CIDAR科学和 基础设施目标。卡彭特博士（The P.I.）和拟议的指导委员会将全面 负责CIDAR的行政职能。指导委员会将包括主要的科学 本申请的领导人：Koenig博士（P.I.：临床前研究核心和项目1）; Thaker博士（P.I.： 研究方法核心和项目#2）;康利和布坎南博士（P.I./ Co-P.I.：项目#3）; McMahon博士 （生物统计学家; Co-P.I.：研究方法核心）;和黄金博士（神经心理学家;共同P.I.;研究 方法核心）。指导委员会将正式审查操作和临床评估核心， 研究方法核心，和临床前研究核心和研究项目活动，每六个月。的 指导委员会还将负责促进博士后研究员的参与 和初级教师在CIDAR活动。在与NIMH计划工作人员协商后，核心将建立一个 外部咨询委员会，并在一开始就与顾问会面，审查计划。外部 咨询委员会将包括来自学术界和工业界的药物发现和开发专家 实验室，与此应用相关的特殊评估专家和生物统计学专家。 核心的临床评估部分将包括：1）生物统计学和数据 管理单位（BDM），将由Robert McMahon博士领导。并将提供服务， 统计咨询和数据库管理;以及2）临床评估股，将由 Robert W.布坎南医学博士临床评估单位将提供：a）可靠和有效的诊断 B）用于评估症状、认知功能和社交的可靠和有效的工具， 职业职能; c）培训如何使用这些工具，以及正在进行的方案内和方案间培训 可靠性会议，以最大限度地提高评级的一致性并控制评级者漂移;以及d）受试者招募 服务

The Operation and Clinical Assessment Core will be responsible for integrating the CIDAR scientific and infrastructure aims. Dr. Carpenter (the P.I.) and the proposed Steering Committee will have overall responsibility for the CIDAR administrative functions. The Steering Committee will include the key scientific leadership for this application: Dr. Koenig (P.I.: Pre-clinical Studies Core and Project #1); Dr. Thaker (P.I.: Research Methods Core and Project #2); Drs. Conley and Buchanan (P.I./Co-P.I.: Project #3); Dr. McMahon (Biostatistician; Co-P.I.: Research Methods Core); and Dr. Gold (Neuropsychologist; Co-P.I.; Research Methods Core). The Steering Committee will formally review the Operation and Clinical Assessment Core, Research Methods Core, and Pre-Clinical Studies Core and research project activities every six months. The Steering Committee will also be responsible for facilitating the involvement of post-doctoral research fellows and junior faculty in CIDAR activities. In consultation with NIMH program staff, the Core will establish an External Advisory Committee and meet with the advisors at the outset to review plans. The External Advisory Committee will include experts in drug discovery and development from academic and industry labs, experts in special assessments relevant to this application, and an expert in biostatistics. The Clinical Assessment component of the Core will be comprised of a: 1) Biostatistics and Data Management Unit (BDM), which will be directed by Robert McMahon, Ph.D. and will provide services in statistical consulting and database management; and 2) Clinical Assessment Unit, which will be directed by Robert W. Buchanan, M.D. The Clinical Assessment Unit will provide: a) reliable and valid diagnostic procedures; b) reliable and valid instruments for assessing symptoms, cognitive function, and social and occupational function; c) training in the use of these instruments, and ongoing intra- and inter-program reliability sessions to maximize consistency in ratings and to control for rater drift; and d) subject recruitment services.